Alliance A031704

Official Title

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab with Cabozantinib for Patients with Advanced Kidney Cancer

Study Purpose

To see how well nivolumab and ipilimumab, followed by nivolumab versus cabozantinib and nivolumab, work in treating renal cell cancer that is untreated and has spread to other parts of the body.

Diagnosis

Eligibility

Renal Cell Carcinoma with clear cell component

Measureable disease

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

Treatment with ipilimumab and nivolumab every 3 weeks for 4 treatments (lasting about 12 weeks). Then, based on scan results, patients will be treated with either nivolumab or cabozantinib, or nivolumab and cabozantinib for up to 1 year.